Filtry
Density of CD20 and CD52 antigens expression on tumor cells in patients with tumors of lymphoid origin in relation to monoclonal antibody treatment (NR9023)
Monoclonal antibodies became a significant and standard part of treatment of various types of cancer. In hematooncology, rituximab (anti-CD20] and alemtuzumab (anti-CD52) are widespread used in treatment of non-Hod...
FD - Onkologie a hematologie
- 2006 - 2008 •
- 1 527 tis. Kč •
- 1 400 tis. Kč •
- MZ
Řešení projektu: 1. 1. 2006 - 31. 12. 2008
Uznané náklady
Podpora ze státního rozpočtu (92%)
Poskytovatel: Ministerstvo zdravotnictví
Predictive stratification of CLL patients for therapy involving monoclonal antibodies targeting CD20 antigen (NV16-32743A)
to therapy involving the antibodies anti-CD20. Methodologically, the project will include. Monoclonal antibodies targeting the surface antigen CD20 contributed to the improvement mutations, which could ha...
FD - Onkologie a hematologie
- 2016 - 2019 •
- 7 664 tis. Kč •
- 7 664 tis. Kč •
- MZ
Řešení projektu: 1. 4. 2016 - 31. 12. 2019
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
*Generic therapeutic antibodies. (2A-2TP1/076)
is conversion of anti-CD20 and anti-CD3 antibodies into practical recombinant formats (1st DNA technologies. The project is oriented onto generic therapeutic antibodies will be hybridoma lines of EXBIO Pr...
EI - Biotechnologie a bionika
- 2007 - 2011 •
- 34 200 tis. Kč •
- 22 230 tis. Kč •
- MPO
Řešení projektu: 1. 6. 2007 - 31. 12. 2011
Uznané náklady
Podpora ze státního rozpočtu (65%)
Poskytovatel: Ministerstvo průmyslu a obchodu
Targeted drug delivery systems for treatment of hematological malignancies (GA15-02986S)
-molecular-weight polymer conjugated with anti-CD20/CD19 MAb. Major advantages anthracyclines targeted by monoclonal antibodies (MAb) for cancer cell-specific therapy as a result of the changed pharmacokinetics and targetin...
FD - Onkologie a hematologie
- 2015 - 2017 •
- 7 942 tis. Kč •
- 7 942 tis. Kč •
- GA ČR
Řešení projektu: 1. 1. 2015 - 31. 12. 2017
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Grantová agentura České republiky
Plant produced recombinant antibodies (IBS5038304)
Properties of recombinant scFv antibodies TU-20, against neuron-specific betaIII-tubulin, and MEM-97, specific for leukocyte antigen CD20, produced in plants characterisation of expressed antibodies. Then MEM-97 will follow...
EC - Imunologie
- 2003 - 2005 •
- 2 480 tis. Kč •
- 1 180 tis. Kč •
- AV ČR
Řešení projektu: 1. 1. 2003 - 1. 1. 2005
Uznané náklady
Podpora ze státního rozpočtu (48%)
Poskytovatel: Akademie věd České republiky
Significance of anti-annexin V antibodies in couples with infertility failures (NH7400)
Creation of ELISA test for detection of anti-annexin V antibodies in couples with infertility failures, comparison with seven antiphospholipid antiphospholipid antibodies. Comparison of serum anti-annexin V ant...
FK - Gynekologie a porodnictví
- 2003 - 2005 •
- 1 796 tis. Kč •
- 1 779 tis. Kč •
- MZ
Řešení projektu: 1. 1. 2003 - 1. 1. 2005
Uznané náklady
Podpora ze státního rozpočtu (99%)
Poskytovatel: Ministerstvo zdravotnictví
Harnessing soluble forms of NK cell receptors and their ligands for the generation of novel anticancer immunotherapeutics (GA15-15181S)
will be prepared in oligomeric form and in fusion with scFv fragment of anti-CD20 antibody will be evaluated on model CD20+ tumor cell line, both individually and in synergy.......
EC - Imunologie
- 2015 - 2019 •
- 6 313 tis. Kč •
- 6 313 tis. Kč •
- GA ČR
Řešení projektu: 1. 1. 2015 - 25. 4. 2019
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Grantová agentura České republiky
Preparation of new radiopharmaceuticals based on monoclonal and recombinant antibodies and peptides labelled by alpha and beta radionuclides (IBS1048301)
A. Choice of approppriate monoclonal antibodies (MABs) and their scFv fragments. The following MABs and their fragments will be examined in the first step: TU-20, an antibody against neuron-specific tubuline, MEM-97, an antibody...
CH - Jaderná a kvantová chemie, fotochemie
- 2003 - 2005 •
- 7 375 tis. Kč •
- 3 731 tis. Kč •
- AV ČR
Řešení projektu: 1. 1. 2003 - 1. 1. 2005
Uznané náklady
Podpora ze státního rozpočtu (51%)
Poskytovatel: Akademie věd České republiky
Modulation of anti-polycyclic aromatic hydrocarbon antibody level in relation to smoking and lung diseases (cancer/non-cancer); and the increase of polycyclic aromatic hydrocarbon resistance (2B06150)
hydrocarbons (PAH). The aim of our project is to determine the level of anti-polycyclic aromatic hydrocarbon (anti-PAH) antibody and the anti-DNA adduct antibody in blood serum induced by PAH. We will stu...
DN - Vliv životního prostředí na zdraví
- 2006 - 2010 •
- 21 000 tis. Kč •
- 17 916 tis. Kč •
- MŠMT
Řešení projektu: 1. 7. 2006 - 31. 7. 2010
Uznané náklady
Podpora ze státního rozpočtu (85%)
Poskytovatel: Ministerstvo školství, mládeže a tělovýchovy
Infertility due to chlamydia infection (NH7026)
of the infectious agent and antibodies to it. Demonstration of chlamydiae in sperm and anti-chlamydia and anti-sperm antibodies in serum and seminal plasma of the male patients. Demonstration of chlamydiae in geni...
FK - Gynekologie a porodnictví
- 2002 - 2004 •
- 2 947 tis. Kč •
- 2 600 tis. Kč •
- MZ
Řešení projektu: 1. 1. 2002 - 1. 1. 2004
Uznané náklady
Podpora ze státního rozpočtu (88%)
Poskytovatel: Ministerstvo zdravotnictví
- 1 - 10 z 1 284